• Soichiro Hanada, Masato Muraki, Yoshiyuki Kawabata, Kazuya Yoshikawa, Toshiyuki Yamagata, Tadao Nagasaki, Yushiro Ohara, Naoki Oiso, Hisako Matsumoto, and Yuji Tohda.
• Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Ikoma, Nara, Japan.
• Patient Prefer Adher. 2023 Jan 1; 17: 284728532847-2853.

Patients And MethodsA questionnaire survey was administered to 18, 14, and 3 patients introduced to home self-injection of dupilumab or mepolizumab using a pen-type device for atopic dermatitis, asthma alone, and asthma plus chronic rhinosinusitis with nasal polyps, respectively.ResultsAll but one participant wished to continue self-injection. Most participants affirmed the reduction in copayment (88.6%) and saving time and labor for hospital visits (88.6%). Six patients who received dupilumab complained of side effects, but all, except for one, continued the treatment. Of the 13 patients who had previously used a syringe-type device, 10 preferred the pen type because of its ease of use, while 3 (23%) preferred the syringe type because of the self-adjustable injection speed for pain control.ConclusionAdministration of biologics using pen-type devices is easier, and the introduction of home self-injection leads to a reduction in outpatient visits and copayment.© 2023 Hanada et al.

6 keywords...

hide…